Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia (CML-CP) who received ≥2 prior tyrosine kinase inhibitors or have the T315I mutation. We report updated results of a phase 1, open-label, nonrandomized trial (NCT02081378) assessing the sa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2023-05, Vol.37 (5), p.1048-1059
Hauptverfasser:	Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, Lang, Fabian
Format:	Artikel
Sprache:	eng
Schlagworte:	38/23 45/77 692/308/153 692/699/1541/1990/283/1896 Adenosine triphosphate Anticancer properties Antineoplastic Agents - therapeutic use Cancer Cancer Research Chronic myeloid leukemia Critical Care Medicine Drug dosages Drug Resistance, Neoplasm Effectiveness Fusion Proteins, bcr-abl - genetics Hematology Hospitals Humans Hypertension Intensive Internal Medicine Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Medicine Medicine & Public Health Mutation Myeloid leukemia Neutropenia Neutropenia - chemically induced Oncology Pancreatitis Philadelphia chromosome Protein Kinase Inhibitors - adverse effects Protein-tyrosine kinase Respiratory tract Respiratory tract diseases Safety Thrombocytopenia Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!